Nutex Health director gets 603 RSUs grant

Nutex Health director Frank E. Jaumot reported receiving a grant of 603 restricted stock units (RSUs) of Nutex Health, Inc. common stock.

Rhea-AI Filing Summary

Nutex Health director Frank E. Jaumot reported receiving a grant of 603 restricted stock units (RSUs) of Nutex Health, Inc. common stock. The RSUs were granted on July 14, 2025 at an exercise price of $0 and are held directly.

Each RSU represents the right to receive one share of Nutex Health common stock upon vesting. The grant vests 100% on July 14, 2026, with a provision for pro-rata vesting based on time served if Jaumot leaves the company without cause during the vesting period.

Insider Trade Summary

Grant/Award: 603 shares

Grant/Award 1 txn

Insider Jaumot Frank E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units (RSUs)	603	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units (RSUs) — 603 contracts (Direct)

Footnotes (2)

1. F1. Each RSU represents a contingence right to receive one share of the issuer's common stock, $0.001 par value, upon vesting.
2. F2. On July 14, 2025, the Reporting Person was granted 603 RSUs, which vest 100% on July 14, 2026. If the Reporting Person leaves service with Company without cause, during the vesting period, the RSUs shall vest on a pro-rata basis for the actual time in service for the Company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nutex Health (NUTX) report for Frank E. Jaumot?

Nutex Health director Frank E. Jaumot reported receiving 603 restricted stock units. These RSUs were granted on July 14, 2025 at a price of $0 per unit and are held directly, representing potential future common stock upon vesting in 2026.

How many RSUs were granted to Nutex Health (NUTX) director Frank E. Jaumot?

Frank E. Jaumot received a grant of 603 restricted stock units. Each RSU represents the right to receive one share of Nutex Health common stock, giving him 603 derivative securities beneficially owned following the reported transaction, all in direct ownership form.

When do the RSUs granted to Nutex Health (NUTX) director Frank E. Jaumot vest?

The 603 RSUs granted to director Frank E. Jaumot vest 100% on July 14, 2026. The filing also states that if he leaves the company without cause during the vesting period, the RSUs will vest on a pro-rata basis based on his actual time in service.

What does each Nutex Health (NUTX) RSU granted to Frank E. Jaumot represent?

Each RSU granted to Frank E. Jaumot represents a contingent right to receive one share of Nutex Health common stock. The common stock has a par value of $0.001 per share, and the RSUs convert into shares only when the vesting conditions are satisfied.

Is the RSU grant to Nutex Health (NUTX) director Frank E. Jaumot a direct holding?

Yes, the filing classifies the 603 restricted stock units as directly owned by Frank E. Jaumot. The ownership form is reported as “D” for direct, and there is no indication of indirect ownership through an intermediary entity or trust in the provided data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 12:51 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jaumot Frank E

(Last) (First) (Middle)

C/O NUTEX HEALTH INC.

6030 S. RICE AVE. SUITE C

(Street)

HOUSTON TX 77081

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nutex Health, Inc. [ NUTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSUs)	$0(1)	07/14/2025		A		603(1)		07/14/2026(2)	07/14/2026(2)	Common Stock	603	$0	603	D

Explanation of Responses:

1. Each RSU represents a contingence right to receive one share of the issuer's common stock, $0.001 par value, upon vesting.

2. On July 14, 2025, the Reporting Person was granted 603 RSUs, which vest 100% on July 14, 2026. If the Reporting Person leaves service with Company without cause, during the vesting period, the RSUs shall vest on a pro-rata basis for the actual time in service for the Company.

	/s/ Frank E. Jaumot	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.